Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02076841
What this trial is testing

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen

Who this might be right for
Relapsing-Remitting Multiple SclerosisClinical Isolated Syndrome (CIS)Multiple Sclerosis
Biogen 40
Post-approval studies (Phase 4)Study completedNCT01310166
What this trial is testing

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 447
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06223074
What this trial is testing

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Who this might be right for
Multiple Sclerosis Relapsing RemittingTreatment
Universidad Nacional Autonoma de Mexico 80
Not applicableStudy completedNCT03205280
What this trial is testing

Clinical Decision Support System (CADIMS) for MS Diagnostic

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Rennes University Hospital 200
Not applicableStudy completedNCT01354665
What this trial is testing

Depression and Fatigue in MS Patients Treated With Betaferon.

Who this might be right for
Multiple Sclerosis
Bayer 567
Testing effectiveness (Phase 2)Study completedNCT01414634
What this trial is testing

Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Universitätsklinikum Hamburg-Eppendorf 9
Post-approval studies (Phase 4)Study completedNCT00112034
What this trial is testing

AVONEX® Combination Trial - "ACT"

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 350
Not applicableStudy completedNCT06526000
What this trial is testing

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Who this might be right for
Relapsing Multiple SclerosisClinically Isolated SyndromeRelapsing-remitting Multiple Sclerosis+1 more
Novartis 326
Not applicableStudy completedNCT01392872
What this trial is testing

Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital, Clermont-Ferrand 48
Not applicableStudy completedNCT02335892
What this trial is testing

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 114
Early research (Phase 1)Looking for participantsNCT03783416
What this trial is testing

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Queen Mary University of London 72
Large-scale testing (Phase 3)Study completedNCT00337779
What this trial is testing

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 1,155
Post-approval studies (Phase 4)Study completedNCT02232061
What this trial is testing

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 6
Not applicableStudy completedNCT04233970
What this trial is testing

Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Universitätsklinikum Hamburg-Eppendorf 160
Not applicableStudy completedNCT07749690
What this trial is testing

Mental Rotation and Motor Imagery Training in Multiple Sclerosis

Who this might be right for
Relapsing Remitting MS (RRMS)
Abant Izzet Baysal University 54
Not applicableStudy completedNCT02403570
What this trial is testing

Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Turku University Hospital 21
Not applicableStudy completedNCT04201470
What this trial is testing

Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple SclerosisProgressive Multiple SclerosisControls+1 more
University Hospital, Montpellier 58
Not applicableStudy completedNCT02275741
What this trial is testing

Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Dr. med. Micha Loebermann 226
Not applicableEnded earlyNCT02394782
What this trial is testing

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Merck KGaA, Darmstadt, Germany 8
Large-scale testing (Phase 3)Study completedNCT00930553
What this trial is testing

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genzyme, a Sanofi Company 1,314
Next Page